| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | sa-mRNA |
| Clinical data | |
| Other names | LUNAR-COV19 |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
ARCT-021, also known asLUNAR-COV19, is aCOVID-19 vaccine candidate developed byArcturus Therapeutics.
It requires theintramuscular injection with a single dose.[2]
ARCT-021 is anself-amplifyingmRNA vaccine.[3][4]
Arcturus Therapeutics partnered with Singapore'sDuke–NUS Medical School to develop aCOVID-19 vaccine.[5] The company also partnered withCatalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19mRNA vaccine candidate.[6]
LUNAR-COV19 clinical trials in humans began in July 2020.[7] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[8]
Arcturus has entered into development and supply agreements with theEconomic Development Board of Singapore and supply agreements with theIsrael Ministry of Health for LUNAR-COV19.[9][10]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
